Logo
x

Search category

Subscribe Now

All Posts by Date

Insights+ Key Biosimilars Events of January 2023

Insights+ Key Biosimilars Events of January 2023

  • February 1, 2023
Biosynex Entered into a Definitive Merger Agreement to Acquire Chembio Diagnostics for ~$17.2M

Biosynex Entered into a Definitive Merger Agreement to Acquire Chembio Diagnostics for ~$17.2M

  • February 1, 2023
Jazz Pharmaceuticals’ Epidyolex (cannabidiol) Receives NICE Recommendation for the Reimbursement to Treat Seizures in England

Jazz Pharmaceuticals’ Epidyolex (cannabidiol) Receives NICE Recommendation for the Reimbursement to Treat Seizures in England

  • February 1, 2023
Roche Receives the EC's Approval for Label Expansion Approval of Hemlibra (emicizumab) for Moderate Haemophilia A

Roche Receives the EC's Approval for Label Expansion Approval of Hemlibra (emicizumab) for Moderate Haemophilia A

  • February 1, 2023
Amgen Launches First Humira (adalimumab) Biosimilar Amjevita in the US

Amgen Launches First Humira (adalimumab) Biosimilar Amjevita in the US

  • February 1, 2023
Context Therapeutics’ Clinical Partner Stemline Therapeutics Receives the US FDA’s Approval of Orserdu (elacestrant) for ER+, HER2-, ESR1-Mutated Breast Cancer

Context Therapeutics’ Clinical Partner Stemline Therapeutics Receives the US FDA’s Approval of Orserdu (elacestrant) for ER+, HER2...

  • February 1, 2023
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.